Ainos' drug VELDONA gets green light for Sjogren's Syndrome trial in Taiwan. Ainos' drug VELDONA gets green light for Sjogren's Syndrome trial in Taiwan.

Ainos، a life sciences firm, has received IRB approval for a clinical trial on Sjogren's Syndrome at Shuang Ho Hospital in Taipei. Ainos, a life sciences firm, has received IRB approval for a clinical trial on Sjogren's Syndrome at Shuang Ho Hospital in Taipei. یہ تجربہ اینوس کی دوا، ولیڈونا کی حفاظت اور موثریت کا جائزہ لے گا، جس نے گزشتہ تجربات میں لعاب کی روانی میں نمایاں بہتری دکھائی ہے۔ The trial will assess the safety and efficacy of Ainos' drug, VELDONA, which has shown significant improvement in salivary flow in previous studies. The study, set to begin in Q1 2025 after a site initiation visit and regulatory approvals, aims to recruit 24 patients for a 24- to 48-week treatment period. The study, set to begin in Q1 2025 after a site initiation visit and regulatory approvals, aims to recruit 24 patients for a 24- to 48-week treatment period.